Guidelines for diagnosis and management of beta-thalassemia intermedia

Pediatric Hematology and Oncology

Volumn 31, Issue 7, 2014, Pages 583-596

  Karimi, Mehran ^a   Cohan, Nader ^a   De Sanctis, Vincenzo ^b   Mallat, Naji S ^c   Taher, Ali ^c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Paediatric and Adolescent Outpatients Clinic   (Italy)

^c AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Beta thalassemia intermedia; Clinical complications; Diagnosis; Management

Indexed keywords

ANTICOAGULANT AGENT; ANTIOXIDANT; CALCIUM; CARNITINE; FERRITIN; FOLIC ACID; HEMOGLOBIN A2; HEMOGLOBIN BETA CHAIN; HEMOGLOBIN F; HEMOGLOBIN GAMMA CHAIN; HYDROXYUREA; IRON; MAGNESIUM CHLORIDE; RECOMBINANT ERYTHROPOIETIN; SILDENAFIL; TRANSFERRIN; VITAMIN D; IMMUNOGLOBULIN; IRON CHELATING AGENT;

ALLOIMMUNIZATION; BETA GLOBIN GENE; BETA THALASSEMIA; BETA THALASSEMIA INTERMEDIA; BLOOD TRANSFUSION; BRAIN ISCHEMIA; CACHEXIA; CEREBROVASCULAR ACCIDENT; DIET SUPPLEMENTATION; DIFFERENTIAL DIAGNOSIS; DYSERYTHROPOIESIS; EXTRAMEDULLARY HEMATOPOIESIS; FERRITIN BLOOD LEVEL; GENE; GENE LOCUS; GENE MUTATION; GENETIC DISORDER; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HETEROZYGOSITY; HUMAN; HYPERCOAGULABILITY; HYPERURICEMIA; INEFFECTIVE ERYTHROPOIESIS; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; LEG ULCER; LUNG EMBOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PORTAL VEIN THROMBOSIS; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; QUALITY OF LIFE; REVIEW; SPLENECTOMY; STEM CELL TRANSPLANTATION; SURVIVAL; THALASSEMIA INTERMEDIA; THALASSEMIA MAJOR; THROMBOEMBOLISM; BETA-THALASSEMIA; BIOSYNTHESIS; COMPLICATION; GENETICS;

BETA-THALASSEMIA; BLOOD TRANSFUSION; GAMMA-GLOBULINS; HUMANS; IRON CHELATING AGENTS; LEG ULCER; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE;

EID: 84907428894     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2014.937884     Document Type: Review

References (64)

1. Olivieri NF. The thalassemias. N Engl J Med. 1999;341:99-109.
2. Rund D, Rachmilewitz E. Thalassemia.N Engl J Med. 2005;353:1135-1146.
3. Haddad A, Tyan P, Radwan A,Mallat N, Taher A. Thalassemia intermedia: A bird's-eye view. Turk J Haematol. 2014;31(1):5-16.
4. Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886-1892.
5. Taher A,Musallam K, Cappellini MD,Weatherall DJ. Optimalmanagement of thalassaemia intermedia. Br J Haematol. 2011;152:512-523.
6. Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: Revisited. Blood Cells Mol Dis. 2006;37:12-20.
7. Camaschella C, Cappellini MD.Thalassemia Intermedia. Haematologica. 1995;80:58-68.
8. El Rassi F, Cappellini MD, Inati A, Taher A. Beta-thalassemia intermedia: An overview. Pediatric Annals. 2008;37(5):322-328.
9. Weatherall DJ. Thalassemia intermedia: cellular and molecular aspects. J Hematol. 2001;86(Suppl 1):186-188.
10. Galanello R, Cao A. Relationship between genotype and phenotype.Thalassemia intermedia. Ann N Y Acad Sci. 1998;850:325-333.
11. Weatherall D.Themolecular basis for phenotypic variability of the common thalassaemias. MolMed Today. 1995;1:15-20.
12. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nature Reviews Genetics. 2001;12:245-255.
13. Moorchung N, Arya V, Agarwal S. Modifier genes and beta thalasaemia intermedia. Haema. 2006;9:505-510.
14. Rachmilewitz A, Giardina P. How I treat thalassemia. Blood. 2011;118(13):3479-3488.
15. Thein SL. Genetic insights into the clinical diversity of beta thalassaemia. Br J Haematol. 2004;(124):264-274.
16. Aessopos A, Kati M,Meletis J.Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion. 2007;47:792-800.
17. Camaschella C, Kattamis AC, Petroni D, et al. Different hematological phenotypes caused by the interaction of triplicated alphaglobin genes and heterozygous beta-thalassemia. Am J Hematol. 1997;(55):83-88.
18. Rachid H, Hani M, Ali TT. Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia. Eur Spine J. 2010;19(6):871-878.
19. Karimi M, Cohan N, Bagheri MH, et al. A lump on the head. Lancet. 2008;372:1436.
20. Karimi M, Cohan N, Pishdad P. Hydroxyurea as a first-line treatment of extramedullary hematopoiesis in patients with beta thalassemia: Four case reports. Hematology. 2014; [Epub ahead of print].
21. Taher A, Isma'eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalas-saemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost. 2006;96:488-491.
22. Taher AT, Musallam KM, Karimi M, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost. 2010;8(10):2152-2158.
23. Karimi M, Bagheri H, Rastgu F, Rachmilewitz E. Magnetic resonance imaging to determine the incidence of brain ischaemia in patients with thalassaemia intermedia. Thromb Haemost. 2010;103:989-993.
24. Musallam KM, Taher AT, Karimi M, Rachmilewitz EA. Cerebral infarction in thalassemia intermedia: breaking the silence. Thromb Res. 2012;130(5):695-702.
25. Manfre L, Giarratano E, Maggio A, et al. MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. AJR Am J Roentgenol. 1999;173(6):1477-1480.
26. Taher AT, Musallam KM, Nasreddine W, et al. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost. 2010;8(1):54-59.
27. Karimi M, Khanlari M, Rachmilewitz E. Cerebrovascular accident in thalassemia major (-TM) and-thalassemia intermedia (-TI). Am J Hematol. 2008;83:77-79.
28. Karimi M, Haghpanah S, Bagheri MH, et al. Frequency and distribution of asymptomatic brain lesions in patients with thalassemia intermedia. Ann Hematol. 2012;91(12):1833-1838.
29. Karimi M, Borzouee M, Mehrabani A, Cohan N. Echocardiographic finding in beta-thalassemia intermedia andmajor: absence of pulmonary hypertension following hydroxyurea treatment in betathalassemia intermedia. Eur J Haematol. 2009;82(3):213-218.
30. Amoozgar H, Farhani N, Karimi M. Risk factors for pulmonary hypertension in patients with thalassemia intermedia. Eur J Haematol. 2011;85:549-551.
31. Karimi M, Musallam KM, Cappellini MD, et al. Risk factors for pulmonary hypertension in patients with thalassemia intermedia. Eur J Intern Med. 2011;22(6):607-610.
32. Gladwin MT, Vichinsky E. Pulmonary complications of sickle cell disease. N Engl J Med. 2008;359:2254-2265.
33. GladwinMT, Lancaster JR Jr, Freeman BA, Schechter AN. Nitric oxide's reactions with hemoglobin: a view through the SNO-storm. NatMed. 2003;9:496-500.
34. Aessopos A, Farmakis D, Tsironi M, et al. Endothelial function and arterial stiffness in sicklethalassemia patients. Atherosclerosis. 2007;191:427-432.
35. De Sanctis V, Tangerini A, TestaMR, et al. Final height and endocrine function in thalassemia intermedia. J Pediatr Endocrinol Metab. 1998;11(Suppl 3):965-971.
36. Harmatz P, Jonas MM, Kwiatkowski JL, et al. Safety and efficacy of pegylated interferon a-2a and ribavirin for the treatment of hepatitis C in patients with thalassemia. Haematologica. 2008;93:1247-1251.
37. Restivo Pantalone G, Renda D, Valenza F, et al. Hepatocellular carcinoma in patients with thalassaemia syndromes: clinical characteristics and outcome in a long term single centre experience. Br J Haematol. 2010;(150):245-247.
38. Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin. 2006;30:119-124.
39. Gamberini MR, Fortini M, De Sanctis V. Healing of leg ulcers with hydroxyurea in thalassaemia intermedia patients with associated endocrine complications. Pediatr Endocrinol Rev. 2004;(Suppl 2):319-322.
40. Matta BN, Abbas O, Maakaron JE, et al. Leg ulcers in patients with thalassaemia intermedia: a single centre's experience. J Eur Acad Dermatol Venereol. 2013; [Epub ahead of print].
41. Derakhshan A, Karimi M, Moghaddam AG. Comparative evaluation of renal finding in betathalassemiamajor and intermedia. Saudi J Kidney Dis Transpl. 2008;19(2):206-209.
42. Karimi M, Nikrooz P, Kashef S, et al. RBC alloimmunization in blood transfusion-dependent betathalassemia patients in southern Iran. Int J Lab Hematol. 2007;29(5):321-326.
43. Spanos T,Karageorga M, LadisV, et al. Red cell alloantibodies in patientswith thalassemia. VoxSang. 1990;58:50-55.
44. Taher AT, Porter JB, Viprakasit V, et al. Deferasirox effectively reduces iron overload in nontransfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study. Ann Hematol. 2013;92(11):1485-1493.
45. Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with beta thalassemia intermedia. Haematologica 2011; 96(11): 1605-1612.
46. Wood JC, Enriquez C, Ghugre N, et al. MRI R2 and R2 mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood. 2005;106(4):1460-1465.
47. Pierre TG, Clark PR, Chua-anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using protonmagnetic resonance. Blood. 2005;105:855-861.
48. Cappellini MD.Overcoming the challenge of patient compliancewith iron chelation therapy. Sem in Hematol. 2005;42:S19-S21.
49. Voskaridou E, Plata E, Douskou M, et al. Treatment with deferasirox (Exjade) effectively decreases iron burden in patients with thalassaemia intermedia: results of a pilot study. Brit J Haematol. 2010;148:332-334.
50. Haghpanah S, Zarei T, Zahedi Z, Karimi M. Compliance and satisfaction with deferasirox (Exjade R) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia. Hematology. 2014;19:187-189.
51. Karimi M, Darzi H, Yavarian M. Hematologic and clinical responses of thalassemia intermedia patients to hydroxyurea during 6 years of therapy in Iran. J Ped Hematol Oncol. 2005;27:380-385.
52. Dixit A, Chatterjee TC,Mishra P, et al. Hydroxyurea in thalassemia intermedia-a promising therapy. Ann Hematol. 2005;84:441-446.
53. Karimi M,Mohammadi F, Behmanesh F, et al. Effect of combination therapy of hydroxyurea with lcarnitine andmagnesium chloride on hematologic parameters and cardiac function of patientswith beta-thalassemia intermedia. Eur J Haematol. 2010; 84: 52-58.
54. Karimi M, Cohan N, Moosavizadeh K, et al. Adverse effects of hydroxyurea in thalassemia intermedia patients: 10 years' experience. Ped Hematol Oncol. 2010;27:205-211.
55. Karimi M, Haghpanah S, Farhadi A, Yavarian M. Genotype-phenotype relationship of patients with thalassemia taking hydroxyurea: a 13-year experience in Iran. Int J Hematol. 2012;95(1):51-56.
56. Karimi M, ZekavatOR,Haghpanah S, et al. Comparative study of hypogonadism in beta-thalassemia intermedia patients with and without hydroxyurea. Hematology. 2012;17(2):122-124.
57. Rachmilewitz EA, Aker M.The role of recombinant human erythropoietin in the treatment of thalassemia. Ann N Y Acad Sci. 1998;850:129-138.
58. Elalfy MS, Adly AA, Ismail EA, et al.Therapeutic superiority and safety of combined hydroxyureawith recombinant human erythropoietin over hydroxyurea in young thalassemia intermedia patients. Eur J Haematol. 2013;91:522-533.
59. Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol. 2000;111:467-473.
60. Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with beta-thalassemic disorders. Int J Hematol. 2003;78:139-145.
61. Cadili A, de Gara C. Complications of splenectomy. Am J ofMed. 2008;121:371-375.
62. Taher AT,Musallam KM, Karimi M, Cappellini MD. Contemporary approaches to treatment of betathalassemia intermedia. Blood Rev. 2012; 26(Suppl 1):S24-S27.
63. Musallam KM, Khoury B, Abi-Habib R, et al.Health-related quality of life in adults with transfusionindependent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights. Eur J Hematol. 2011;87:73-79.
64. Pakbaz Z, Treadwell M, Yamashita R, et al. Quality of life in patients with thalassemia intermedia compared to thalassemiamajor. Ann N Y Acad Sci. 2005;1054:457-461.